FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
moduction ±(b).

			or Section 30(n) of the investment Company Act of 1940			
Name and Address of Reporting Person* Suri Anish			2. Issuer Name and Ticker or Trading Symbol Cue Biopharma, Inc. [CUE]		ationship of Reporting Pe all applicable) Director Officer (give title	rson(s) to Issuer 10% Owner Other (specify below)
(Last) (First) (Middle) C/O CUE BIOPHARMA, INC. 21 ERIE STREET		,	3. Date of Earliest Transaction (Month/Day/Year) 11/11/2021		President an	,
(Street) CAMBRIDGE (City)	MA (State)	02139 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	ridual or Joint/Group Filir Form filed by One Rej Form filed by More the Person	porting Person
		Table I Non De	privative Securities Assuired Disposed of ar Pon	oficially	Owned	

curities Acquired, Disposed of, or Beneficially Owned 6. Ownership Form: Direct (D) or Indirect 2A. Deemed Execution Date, 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 7. Nature 1. Title of Security (Instr. 3) 2. Transaction 5. Amount of Securities Beneficially of Indirect Beneficial Transaction (Month/Day/Year) if any (Month/Day/Year) Code (Instr. 8) Owned Following Reported (I) (Instr. 4) Ownership (Instr. 4) Transaction(s) (Instr. 3 and 4) (A) or (D) ν Price Code Amount M⁽¹⁾ Common Stock 11/11/2021 20,000 A \$6.42 114,038 D **S**(1) \$15.0677(2) 11/11/2021 20,000 94,038 D Common Stock D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1	1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
1	Stock Option (right to buy)	\$6.42	11/11/2021		M ⁽¹⁾			20,000	(3)	03/06/2029	Common Stock	20,000	\$0.00	105,000	D		

Explanation of Responses:

- 1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$15.00 to \$15.29, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
- 3. The option vests in eight equal semi-annual installments beginning September 6, 2019.

Remarks:

/s/ Anish Suri by Colin Sandercock, attorney-in-fact ** Signature of Reporting Person

11/15/2021 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.